The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 2, 2012, Pages 141-145

  Enriquez, Miriam L ^a   Lal, Priti ^a   Ziober, Amy ^a   Wang, Liping ^a   Tomaszewski, John E ^a   Bing, Zhanyong ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adrenal; epithelial membrane antigen; renal; steroidogenic factor 1

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; STEROIDOGENIC FACTOR 1;

ADRENAL CORTEX; ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ARTICLE; CHROMOPHOBE ADENOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY TUMOR; MAJOR CLINICAL STUDY; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CELL;

ADENOMA, OXYPHILIC; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MUCIN-1; NEOPLASM PROTEINS; RETROSPECTIVE STUDIES; STEROIDOGENIC FACTOR 1;

EID: 84862786247     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31823605e7     Document Type: Article

References (22)

1. Mantero F, Arnaldi G. Management approaches to adrenal incidentalomas. A View from Ancona, Italy, Endocrinol Metab Clin North Am. 2000;29:107-125. ix.
2. Reincke M, Beuschlein F, Slawik M, et al. Molecular adrenocortical tumourigenesis. Eur J Clin Invest. 2000;30(Suppl 3):63-68. (Pubitemid 32162084)
3. Ren R, Guo M, Sneige N, et al. Fine-needle aspiration of adrenal cortical carcinoma: cytologic spectrum and diagnostic challenges. Am J Clin Pathol. 2006;126:389-398. (Pubitemid 44338791)
4. Golden SH, Robinson KA, Saldanha I, et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853-1878.
5. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:757-768.
6. Ohtake H, Kawamura H, Matsuzaki M, et al. Oncocytic adreno-cortical carcinoma. Ann Diagn Pathol. 2010;14:204-208.
7. Tirkes T, Gokaslan T, McCrea J, et al. Oncocytic neoplasms of the adrenal gland. AJR Am J Roentgenol. 2011;196:592-596.
8. Wong DD, Spagnolo DV, Bisceglia M, et al. Oncocytic adrenocortical neoplasms-a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. Hum Pathol. 2011;42:489-499.
9. Ishida M, Kojima K, Ohtomo K. Renal cell carcinoma with double synchronous contralateral adrenal metastases. Korean J Urol. 2010;51:879-881.
10. Angervall L, Wahlqvist L. Follow-up and prognosis of renal carcinoma in a series operated by perifascial nephrectomy combined with adrenalectomy and retroperitoneal lymphadenectomy. Eur Urol. 1978;4:13-17. (Pubitemid 8266878)
11. Robey EL, Schellhammer PF. The adrenal gland and renal cell carcinoma: is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol. 1986;135:453-455. (Pubitemid 16163460)
12. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984;8: 163-169. (Pubitemid 14166767)
13. Schimmer BP, White PC. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol 2010;24:1322-1337.
14. Sbiera S, Schmull S, Assie G, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab. 2010;95:E161-171.
15. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678-686.
16. Morohashi K, Honda S, Inomata Y, et al. A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s. J Biol Chem. 1992;267:17913-17919.
17. Kaneko T, Sasaki S, Umemoto Y, et al. Simulated conditions of microgravity increases progesterone production in I-10 cells of Leydig tumor cell line. Int J Urol. 2008;15:245-250. (Pubitemid 351316935)
18. Sasano H, Shizawa S, Nagura H. Adrenocortical cytopathology. Am J Clin Pathol. 1995;104:161-166.
19. Sasano H, Shizawa S, Suzuki T, et al. Ad4BP in the human adrenal cortex and its disorders. J Clin Endocrinol Metab. 1995;80:2378-2380.
20. Sasano H, Shizawa S, Suzuki T, et al. Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol. 1995;26:1154-1156.
21. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195-1201. (Pubitemid 20137851)
22. Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocor-tical tumors. Am J Surg Pathol. 2002;26:1612-1619. (Pubitemid 35387224)